3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
4
Wound Infection
2
Infections
2
Surgical Wound Infection
1
Prostatic Neoplasms
1
Laryngeal Neoplasms
1
Clinical Stage I Cutaneous Melanoma AJCC v8
1
Bone Neoplasms
1
Interventions
Gemcitabine
7
Doxorubicin
4
Cyclophosphamide
4
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Docetaxel
3
Cisplatin
3
regorafenib
2
Vincristine
2
Tranexamic Acid
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
Radiation
2
Proton Therapy
2
Nivolumab
2
Methotrexate
2
Methods
2
Interviews as Topic
2
Indocyanine Green
2
Everolimus
2
Curettage
2
Ascorbic Acid
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tocilizumab
1
samarium Sm-153 lexidronam
1
poly ICLC
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Bone Neoplasms
×
Cefazolin
×
Clear all
NCT01479283
2021-03-11
PARITY
McMaster University
Phase 3
Completed
602 enrolled